Cancer Treatment Reviews
Volume 31, Issue 8 , Pages 603-617 , December 2005

The emerging role of DNA repair proteins as predictive, prognostic and therapeutic targets in cancer

References 

  1. Sancar A, Lindsey-Boltz LA, Unsal-Kaccmaz K, Linn S. Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints. Annu Rev Biochem. 2004;73:39–85
  2. Gerson SL. MGMT: its role in cancer aetiology and cancer therapeutics. Nat Rev Cancer. 2004;4:296–307
  3. Dianov GL, Sleeth KM, Dianova , Allinson SL. Repair of abasic sites in DNA. Mutat Res. 2003;531:157–163
  4. Bassing CH, Alt FW. The cellular response to general and programmed DNA double strand breaks. DNA Repair (Amst). 2004;3:781–796
  5. Willers H, Dahm-Daphi J, Powell SN. Repair of radiation damage to DNA. Br J Cancer. 2004;90:1297–1301
  6. Lees-Miller SP, Meek K. Repair of DNA double strand breaks by non-homologous end joining. Biochimie. 2003;85:1161–1173
  7. Dudas A, Chovanec M. DNA double-strand break repair by homologous recombination. Mutat Res. 2004;566:131–167
  8. Costa RM, Chigancas V, Galhardo Rda S, Carvalho H, Menck CF. The eukaryotic nucleotide excision repair pathway. Biochimie. 2003;85:1083–1099
  9. Schofield MJ, Hsieh P. DNA mismatch repair: molecular mechanisms and biological function. Annu Rev Microbiol. 2003;57:579–608
  10. Peltomaki P. Role of DNA mismatch repair defects in the pathogenesis of human cancer. J Clin Oncol. 2003;21:1174–1179
  11. Jagtap P, Szabo C. Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors. Nat Rev Drug Discov. 2005;4:421–440
  12. Bouchard VJ, Rouleau M, Poirier GG. PARP-1, a determinant of cell survival in response to DNA damage. Exp Hematol. 2003;31:446–454
  13. Allinson SL, Dianova , Dianov GL. Poly(ADP-ribose) polymerase in base excision repair: always engaged, but not essential for DNA damage processing. Acta Biochim Pol. 2003;50:169–179
  14. Kraus WL, Lis JT. PARP goes transcription. Cell. 2003;113:677–683
  15. Hoeijmakers JH. Genome maintenance mechanisms for preventing cancer. Nature. 2001;411:366–374
  16. Brookes AJ. The essence of SNPs. Gene. 1999;234:177–186
  17. Schmith VD, Campbell DA, Sehgal S, Anderson WH, Burns DK, Middleton LT, et al. Pharmacogenetics and disease genetics of complex diseases. Cell Mol Life Sci. 2003;60:1636–1646
  18. Roses AD. Pharmacogenetics and the practice of medicine. Nature. 2000;405:857–865
  19. Goode EL, Ulrich CM, Potter JD. Polymorphisms in DNA repair genes and associations with cancer risk. Cancer Epidemiol Biomarkers Prev. 2002;11:1513–1530
  20. de Boer JG. Polymorphisms in DNA repair and environmental interactions. Mutat Res. 2002;509:201–210
  21. Kiyohara C, Otsu A, Shirakawa T, Fukuda S, Hopkin JM. Genetic polymorphisms and lung cancer susceptibility: a review. Lung Cancer. 2002;37:241–256
  22. Misra RR, Ratnasinghe D, Tangrea JA, Virtamo J, Andersen MR, Barrett M, et al. Polymorphisms in the DNA repair genes XPD, XRCC1, XRCC3, and APE/ref-1, and the risk of lung cancer among male smokers in Finland. Cancer Lett. 2003;191:171–178
  23. Gurubhagavatula S, Liu G, Park S, Zhou W, Su L, Wain JC, et al. XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy. J Clin Oncol. 2004;22:2594–2601
  24. Camps C, Sarries C, Roig B, Sanchez JJ, Queralt C, Sancho E, et al. Assessment of nucleotide excision repair XPD polymorphisms in the peripheral blood of gemcitabine/cisplatin-treated advanced non-small-cell lung cancer patients. Clin Lung Cancer. 2003;4:237–241
  25. Zhou W, Gurubhagavatula S, Liu G, Park S, Neuberg DS, Wain JC, et al. Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy. Clin Cancer Res. 2004;10:4939–4943
  26. Esteller M, Hamilton SR, Burger PC, Baylin SB, Herman JG. Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res. 1999;59:793–797
  27. Park TJ, Han SU, Cho YK, Paik WK, Kim YB, Lim IK. Methylation of O(6)-methylguanine-DNA methyltransferase gene is associated significantly with K-ras mutation, lymph node invasion, tumor staging, and disease free survival in patients with gastric carcinoma. Cancer. 2001;92:2760–2768
  28. Hayashi H, Yazawa T, Okudela K, Nagai J, Ito T, Kanisawa M, et al. Inactivation of O6-methylguanine-DNA methyltransferase in human lung adenocarcinoma relates to high-grade histology and worse prognosis among smokers. Jpn J Cancer Res. 2002;93:184–189
  29. Kohya N, Miyazaki K, Matsukura S, Yakushiji H, Kitajima Y, Kitahara K, et al. Deficient expression of O(6)-methylguanine-DNA methyltransferase combined with mismatch-repair proteins hMLH1 and hMSH2 is related to poor prognosis in human biliary tract carcinoma. Ann Surg Oncol. 2002;9:371–379
  30. Esteller M, Gaidano G, Goodman SN, Zagonel V, Capello D, Botto B, et al. Hypermethylation of the DNA repair gene O(6)-methylguanine DNA methyltransferase and survival of patients with diffuse large B-cell lymphoma. J Natl Cancer Inst. 2002;94:26–32
  31. Esteller M, Garcia-Foncillas J, Andion E, Goodman SN, Hidalgo OF, Vanaclocha V, et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med. 2000;343:1350–1354
  32. Jaeckle KA, Eyre HJ, Townsend JJ, Schulman S, Knudson HM, Belanich M, et al. Correlation of tumor O6 methylguanine-DNA methyltransferase levels with survival of malignant astrocytoma patients treated with bis-chloroethylnitrosourea: a Southwest Oncology Group study. J Clin Oncol. 1998;16:3310–3315
  33. Hegi ME, Diserens AC, Godard S, Dietrich PY, Regli L, Ostermann S, et al. Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clin Cancer Res. 2004;10:1871–1874
  34. Paz MF, Yaya-Tur R, Rojas-Marcos I, Reynes G, Pollan M, Aguirre-Cruz L, et al. CpG island hypermethylation of the DNA repair enzyme methyltransferase predicts response to temozolomide in primary gliomas. Clin Cancer Res. 2004;10:4933–4938
  35. Bosken CH, Wei Q, Amos CI, Spitz MR. An analysis of DNA repair as a determinant of survival in patients with non-small-cell lung cancer. J Natl Cancer Inst. 2002;94:1091–1099
  36. Rosell R, Taron M, Barnadas A, Scagliotti G, Sarries C, Roig B. Nucleotide excision repair pathways involved in Cisplatin resistance in non-small-cell lung cancer. Cancer Contr. 2003;10:297–305
  37. Lord RV, Brabender J, Gandara D, Alberola V, Camps C, Domine M, et al. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res. 2002;8:2286–2291
  38. Ai L, Vo QN, Zuo C, Li L, Ling W, Suen JY, et al. Ataxia-telangiectasia-mutated (ATM) gene in head and neck squamous cell carcinoma: promoter hypermethylation with clinical correlation in 100 cases. Cancer Epidemiol Biomarkers Prev. 2004;13:150–156
  39. Starostik P, Manshouri T, O’Brien S, Freireich E, Kantarjian H, Haidar M, et al. Deficiency of the ATM protein expression defines an aggressive subgroup of B-cell chronic lymphocytic leukemia. Cancer Res. 1998;58:4552–4557
  40. Korabiowska M, Tscherny M, Grohmann U, Honig JF, Bartkowski SB, Cordon-Cardo C, et al. Decreased expression of Ku70/Ku80 proteins in malignant melanomas of the oral cavity. Anticancer Res. 2002;22:193–196
  41. Korabiowska M, Tscherny M, Stachura J, Berger H, Cordon-Cardo C, Brinck U. Differential expression of DNA nonhomologous end-joining proteins Ku70 and Ku80 in melanoma progression. Mod Pathol. 2002;15:426–433
  42. Komuro Y, Watanabe T, Hosoi Y, Matsumoto Y, Nakagawa K, Tsuno N, et al. The expression pattern of Ku correlates with tumor radiosensitivity and disease free survival in patients with rectal carcinoma. Cancer. 2002;95:1199–1205
  43. Komuro Y, Watanabe T, Hosoi Y, Matsumoto Y, Nakagawa K, Saito S, et al. Prediction of tumor radiosensitivity in rectal carcinoma based on p53 and Ku70 expression. J Exp Clin Cancer Res. 2003;22:223–228
  44. Brueckl WM, Moesch C, Brabletz T, Koebnick C, Riedel C, Jung A, et al. Relationship between microsatellite instability, response and survival in palliative patients with colorectal cancer undergoing first-line chemotherapy. Anticancer Res. 2003;23:1773–1777
  45. Jansson A, Arbman G, Zhang H, Sun XF. Combined deficiency of hMLH1, hMSH2, hMSH3 and hMSH6 is an independent prognostic factor in colorectal cancer. Int J Oncol. 2003;22:41–49
  46. Kakar S, Aksoy S, Burgart LJ, Smyrk TC. Mucinous carcinoma of the colon: correlation of loss of mismatch repair enzymes with clinicopathologic features and survival. Mod Pathol. 2004;17:696–700
  47. Son BH, Ahn SH, Ko CD, Ka IW, Gong GY, Kim JC. Significance of mismatch repair protein expression in the chemotherapeutic response of sporadic invasive ductal carcinoma of the breast. Breast J. 2004;10:20–26
  48. Velasco A, Hewitt SM, Albert PS, Hossein M, Rosenberg H, Martinez C, et al. Differential expression of the mismatch repair gene hMSH2 in malignant prostate tissue is associated with cancer recurrence. Cancer. 2002;94:690–699
  49. Brueckl WM, Heinze E, Milsmann C, Wein A, Koebnick C, Jung A, et al. Prognostic significance of microsatellite instability in curatively resected adenocarcinoma of the small intestine. Cancer Lett. 2004;203:181–190
  50. Taubert HW, Bartel F, Kappler M, Schuster K, Meye A, Lautenschlager C, et al. Reduced expression of hMSH2 protein is correlated to poor survival for soft tissue sarcoma patients. Cancer. 2003;97:2273–2278
  51. Nakata B, Wang YQ, Yashiro M, Ohira M, Ishikawa T, Nishino H, et al. Negative hMSH2 protein expression in pancreatic carcinoma may predict a better prognosis of patients. Oncol Rep. 2003;10:997–1000
  52. Catto JW, Xinarianos G, Burton JL, Meuth M, Hamdy FC. Differential expression of hMLH1 and hMSH2 is related to bladder cancer grade, stage and prognosis but not microsatellite instability. Int J Cancer. 2003;105:484–490
  53. Brooks KR, To K, Joshi MB, Conlon DH, Herndon JE, D’Amico TA, et al. Measurement of chemoresistance markers in patients with stage III non-small cell lung cancer: a novel approach for patient selection. Ann Thorac Surg. 2003;76:187–193discussion 93
  54. Gerson SL, Berger NA, Arce C, Petzold SJ, Willson JK. Modulation of nitrosourea resistance in human colon cancer by O6-methylguanine. Biochem Pharmacol. 1992;43:1101–1107
  55. Gerson SL, Willson JK. O6-alkylguanine-DNA alkyltransferase. A target for the modulation of drug resistance. Hematol Oncol Clin North Am. 1995;9:431–450
  56. Fujio C, Chang HR, Tsujimura T, Ishizaki K, Kitamura H, Ikenaga M. Hypersensitivity of human tumor xenografts lacking O6-alkylguanine-DNA alkyltransferase to the anti-tumor agent 1-(4-amino-2-methyl-5-pyrimidinyl)methyl-3-(2-chloroethyl)-3-nitrosourea. Carcinogenesis. 1989;10:351–356
  57. Middleton MR, Margison GP. Improvement of chemotherapy efficacy by inactivation of a DNA-repair pathway. Lancet Oncol. 2003;4:37–44
  58. Chang SM, Prados MD, Yung WK, Fine H, Junck L, Greenberg H, et al. Phase II study of neoadjuvant 1,3-bis (2-chloroethyl)-1-nitrosourea and temozolomide for newly diagnosed anaplastic glioma: a North American Brain Tumor Consortium Trial. Cancer. 2004;100:1712–1716
  59. Tolcher AW, Gerson SL, Denis L, Geyer C, Hammond LA, Patnaik A, et al. Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules. Br J Cancer. 2003;88:1004–1011
  60. Dolan ME, Moschel RC, Pegg AE. Depletion of mammalian O6-alkylguanine-DNA alkyltransferase activity by O6-benzylguanine provides a means to evaluate the role of this protein in protection against carcinogenic and therapeutic alkylating agents. Proc Natl Acad Sci USA. 1990;87:5368–5372
  61. Tserng KY, Ingalls ST, Boczko EM, Spiro TP, Li X, Majka S, et al. Pharmacokinetics of O6-benzylguanine (NSC637037) and its metabolite, 8-oxo-O6-benzylguanine. J Clin Pharmacol. 2003;43:881–893
  62. Middleton MR, Thatcher N, McMurry TB, McElhinney RS, Donnelly DJ, Margison GP. Effect of O6-(4-bromothenyl)guanine on different temozolomide schedules in a human melanoma xenograft model. Int J Cancer. 2002;100:615–617
  63. Middleton MR, Kelly J, Thatcher N, Donnelly DJ, McElhinney RS, McMurry TB, et al. O(6)-(4-bromothenyl)guanine improves the therapeutic index of temozolomide against A375M melanoma xenografts. Int J Cancer. 2000;85:248–252
  64. Liu L, Gerson SL. Therapeutic impact of methoxyamine: blocking repair of abasic sites in the base excision repair pathway. Curr Opin Investig Drugs. 2004;5:623–627
  65. Izumi T, Wiederhold LR, Roy G, Roy R, Jaiswal A, Bhakat KK, et al. Mammalian DNA base excision repair proteins: their interactions and role in repair of oxidative DNA damage. Toxicology. 2003;193:43–65
  66. Boiteux S, Guillet M. Abasic sites in DNA: repair and biological consequences in Saccharomyces cerevisiae. DNA Repair (Amst). 2004;3:1–12
  67. Dizdaroglu M. Substrate specificities and excision kinetics of DNA glycosylases involved in base-excision repair of oxidative DNA damage. Mutat Res. 2003;531:109–126
  68. Dodson ML, Lloyd RS. Mechanistic comparisons among base excision repair glycosylases. Free Radic Biol Med. 2002;32:678–682
  69. Wilson DM, Barsky D. The major human abasic endonuclease: formation, consequences and repair of abasic lesions in DNA. Mutat Res. 2001;485:283–307
  70. Weinfeld M. Complexities of BER. Prog Nucleic Acid Res Mol Biol. 2001;68:125–127
  71. Hollis T, Lau A, Ellenberger T. Crystallizing thoughts about DNA base excision repair. Prog Nucleic Acid Res Mol Biol. 2001;68:305–314
  72. Evans AR, Limp-Foster M, Kelley MR. Going APE over ref-1. Mutat Res. 2000;461:83–108
  73. Frosina G. Overexpression of enzymes that repair endogenous damage to DNA. Eur J Biochem. 2000;267:2135–2149
  74. Liu L, Taverna P, Whitacre CM, Chatterjee S, Gerson SL. Pharmacologic disruption of base excision repair sensitizes mismatch repair-deficient and -proficient colon cancer cells to methylating agents. Clin Cancer Res. 1999;5:2908–2917
  75. Taverna P, Liu L, Hwang HS, Hanson AJ, Kinsella TJ, Gerson SL. Methoxyamine potentiates DNA single strand breaks and double strand breaks induced by temozolomide in colon cancer cells. Mutat Res. 2001;485:269–281
  76. Liu L, Nakatsuru Y, Gerson SL. Base excision repair as a therapeutic target in colon cancer. Clin Cancer Res. 2002;8:2985–2991
  77. Meihua Luo DC, Yi Xu, Ying He, April Reed, Hiroshi Handa, Kelley Mark R. Inhibition of the human apurinic/apyrimidinic endonuclease DNA base excision repair enzyme/redox factor (APE1/Ref-1) using small molecule redox and repair inhibitors; therapeutic implications. American Association for Cancer Research meeting (Abstract No. 3042), Orlando, FL, USA; 2004.
  78. Madhusudan S, Smart F, Houlbrook S, Talbot DC, Hammonds T, Hickson ID. Identification and characterisation of small molecule chemical inhibitors of human apurinic/apyrimidinic (AP) endonuclease (HAP-1) for cancer therapy. American Association for Cancer Research (Abstract No. 5366), Orlando, FL, USA; 2004.
  79. Li L, Berger SH, Wyatt MD. Involvement of base excision repair in response to therapy targeted at thymidylate synthase. Mol Cancer Ther. 2004;3:747–753
  80. Molinete M, Vermeulen W, Burkle A, Menissier-de Murcia J, Kupper JH, Hoeijmakers JH, et al. Overproduction of the poly(ADP-ribose) polymerase DNA-binding domain blocks alkylation-induced DNA repair synthesis in mammalian cells. EMBO J. 1993;12:2109–2117
  81. de Murcia JM, Niedergang C, Trucco C, Ricoul M, Dutrillaux B, Mark M, et al. Requirement of poly(ADP-ribose) polymerase in recovery from DNA damage in mice and in cells. Proc Natl Acad Sci USA. 1997;94:7303–7307
  82. Van Gool L, Meyer R, Tobiasch E, Cziepluch C, Jauniaux JC, Mincheva A, et al. Overexpression of human poly(ADP-ribose) polymerase in transfected hamster cells leads to increased poly(ADP-ribosyl)ation and cellular sensitization to gamma irradiation. Eur J Biochem. 1997;244:15–20
  83. Rudat V, Kupper JH, Weber KJ. Trans-dominant inhibition of poly(ADP-ribosyl)ation leads to decreased recovery from ionizing radiation-induced cell killing. Int J Radiat Biol. 1998;73:325–330
  84. Hans MA, Muller M, Meyer-Ficca M, Burkle A, Kupper JH. Overexpression of dominant negative PARP interferes with tumor formation of HeLa cells in nude mice: evidence for increased tumor cell apoptosis in vivo. Oncogene. 1999;18:7010–7015
  85. Southan GJ, Szabo C. Poly(ADP-ribose) polymerase inhibitors. Curr Med Chem. 2003;10:321–340
  86. Griffin RJ, Curtin NJ, Newell DR, Golding BT, Durkacz BW, Calvert AH. The role of inhibitors of poly(ADP-ribose) polymerase as resistance-modifying agents in cancer therapy. Biochimie. 1995;77:408–422
  87. Griffin RJ, Srinivasan S, Bowman K, Calvert AH, Curtin NJ, Newell DR, et al. Resistance-modifying agents. 5. Synthesis and biological properties of quinazolinone inhibitors of the DNA repair enzyme poly(ADP-ribose) polymerase (PARP). J Med Chem. 1998;41:5247–5256
  88. White AW, Curtin NJ, Eastman BW, Golding BT, Hostomsky Z, Kyle S, et al. Potentiation of cytotoxic drug activity in human tumour cell lines, by amine-substituted 2-arylbenzimidazole-4-carboxamide PARP-1 inhibitors. Bioorg Med Chem Lett. 2004;14:2433–2437
  89. Beneke S, Diefenbach J, Burkle A. Poly(ADP-ribosyl)ation inhibitors: promising drug candidates for a wide variety of pathophysiologic conditions. Int J Cancer. 2004;111:813–818
  90. Bowman KJ, White A, Golding BT, Griffin RJ, Curtin NJ. Potentiation of anti-cancer agent cytotoxicity by the potent poly(ADP-ribose) polymerase inhibitors NU1025 and NU1064. Br J Cancer. 1998;78:1269–1277
  91. Delaney CA, Wang LZ, Kyle S, White AW, Calvert AH, Curtin NJ, et al. Potentiation of temozolomide and topotecan growth inhibition and cytotoxicity by novel poly(adenosine diphosphoribose) polymerase inhibitors in a panel of human tumor cell lines. Clin Cancer Res. 2000;6:2860–2867
  92. White AW, Almassy R, Calvert AH, Curtin NJ, Griffin RJ, Hostomsky Z, et al. Resistance-modifying agents. 9. Synthesis and biological properties of benzimidazole inhibitors of the DNA repair enzyme poly(ADP-ribose) polymerase. J Med Chem. 2000;43:4084–4097
  93. Skalitzky DJ, Marakovits JT, Maegley KA, Ekker A, Yu XH, Hostomsky Z, et al. Tricyclic benzimidazoles as potent poly(ADP-ribose) polymerase-1 inhibitors. J Med Chem. 2003;46:210–213
  94. Calabrese CR, Almassy R, Barton S, Batey MA, Calvert AH, Canan-Koch S, et al. Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361. J Natl Cancer Inst. 2004;96:56–67
  95. Calabrese CR, Batey MA, Thomas HD, Durkacz BW, Wang LZ, Kyle S, et al. Identification of potent nontoxic poly(ADP-Ribose) polymerase-1 inhibitors: chemopotentiation and pharmacological studies. Clin Cancer Res. 2003;9:2711–2718
  96. Veuger SJ, Curtin NJ, Richardson CJ, Smith GC, Durkacz BW. Radiosensitization and DNA repair inhibition by the combined use of novel inhibitors of DNA-dependent protein kinase and poly(ADP-ribose) polymerase-1. Cancer Res. 2003;63:6008–6015
  97. Veuger SJ, Curtin NJ, Smith GC, Durkacz BW. Effects of novel inhibitors of poly(ADP-ribose) polymerase-1 and the DNA-dependent protein kinase on enzyme activities and DNA repair. Oncogene. 2004;23:7322–7329
  98. Li G, Li X, Zhang J, Xu W, Calvin DC, Morgan L, et al. GPI 15427, a PARP inhibitor, enhances radiation treatment in a human xenograft head and neck model. Amercian Association for Cancer Research (Abstract No. 1359), Orlando, FL, USA; 2004.
  99. Tentori L, Leonetti C, Scarsella M, Xu W, Calvin D, Morgan L, et al. Oral administration of the PARP-1 inhibitor GPI 15427 increases the anti-tumor activity of temozolomide against melanoma growing at the CNS site. American Association for Cancer Research (Abstract No. 2007), Orlando, FL, USA; 2004.
  100. Miknyoczki SJ, Jones-Bolin S, Pritchard S, Hunter K, Zhao H, Wan W, et al. Chemopotentiation of temozolomide, irinotecan, and cisplatin activity by CEP-6800, a poly(ADP-ribose) polymerase inhibitor. Mol Cancer Ther. 2003;2:371–382
  101. Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature. 2005;434:913–917
  102. Caldecott K, Jeggo P. Cross-sensitivity of gamma-ray-sensitive hamster mutants to cross-linking agents. Mutat Res. 1991;255:111–121
  103. Tanaka T, Yamagami T, Oka Y, Nomura T, Sugiyama H. The scid mutation in mice causes defects in the repair system for both double-strand DNA breaks and DNA cross-links. Mutat Res. 1993;288:277–280
  104. Muller C, Salles B. Regulation of DNA-dependent protein kinase activity in leukemic cells. Oncogene. 1997;15:2343–2348
  105. Muller C, Christodoulopoulos G, Salles B, Panasci L. DNA-dependent protein kinase activity correlates with clinical and in vitro sensitivity of chronic lymphocytic leukemia lymphocytes to nitrogen mustards. Blood. 1998;92:2213–2219
  106. Christodoulopoulos G, Muller C, Salles B, Kazmi R, Panasci L. Potentiation of chlorambucil cytotoxicity in B-cell chronic lymphocytic leukemia by inhibition of DNA-dependent protein kinase activity using wortmannin. Cancer Res. 1998;58:1789–1792
  107. Ortiz T, Lopez S, Burguillos MA, Edreira A, Pinero J. Radiosensitizer effect of wortmannin in radioresistant bladder tumoral cell lines. Int J Oncol. 2004;24:169–175
  108. Oliveira NG, Castro M, Rodrigues AS, Gil OM, Toscano-Rico JM, Rueff J. DNA-PK inhibitor wortmannin enhances DNA damage induced by bleomycin in V79 Chinese hamster cells. Teratog Carcinog Mutagen. 2002;22:343–351
  109. Stockley M, Clegg W, Fontana G, Golding BT, Martin N, Rigoreau LJ, et al. Synthesis, crystal structure determination, and biological properties of the DNA-dependent protein kinase (DNA-PK) inhibitor 3-cyano-6-hydrazonomethyl-5-(4-pyridyl)pyrid-[1H]-2-one (OK-1035). Bioorg Med Chem Lett. 2001;11:2837–2841
  110. Okayasu R, Takakura K, Poole S, Bedford JS. Radiosensitization of normal human cells by LY294002: cell killing and the rejoining of DNA and interphase chromosome breaks. J Radiat Res (Tokyo). 2003;44:329–333
  111. Gupta AK, Cerniglia GJ, Mick R, Ahmed MS, Bakanauskas VJ, Muschel RJ, et al. Radiation sensitization of human cancer cells in vivo by inhibiting the activity of PI3K using LY294002. Int J Radiat Oncol Biol Phys. 2003;56:846–853
  112. Veuger SJ, Curtin NJ, Smith GC, Durkacz BW. Effects of novel inhibitors of poly(ADP-ribose) polymerase-1 and the DNA-dependent protein kinase on enzyme activities and DNA repair. Oncogene. 2004;
  113. Willmore E, Cowell IG, Jackson GH, Austin CA, Durkacz BW. Use of novel DNA repair inhibitors to potentiate the cytotoxicity of agents used to treat chronic lymphocytic leukemia. American Association for Cancer Research (Abstract No. 3030), Orlando, FL, USA; 2004.
  114. Griffin RJ, Curtin NJ, Golding BT, Guiard S, Hardcastle IR, Leahy JJ, et al. Identification of the potent and selective DNA-dependent protein kinase (DNA-PK) inhibitor NU7441 by screening of chromenone libraries. American Association for Cancer Research (Abstract No. 5362), Orlando, FL, USA; 2004.
  115. Shinohara E, Halbrook J, Geng L, Xia F, Hallahan DE. Radiosensatization by the novel DNA-Dependent Protein Kinase (DNA-PK) inhibitors, IC87102 and IC87361 in animal tumor models. American Association for Cancer Research (Abstract No. 1353), Orlando, FL, USA; 2004.
  116. Collis SJ, Swartz MJ, Nelson WG, DeWeese TL. Enhanced radiation and chemotherapy-mediated cell killing of human cancer cells by small inhibitory RNA silencing of DNA repair factors. Cancer Res. 2003;63:1550–1554
  117. Sak A, Stuschke M, Wurm R, Schroeder G, Sinn B, Wolf G, et al. Selective inactivation of DNA-dependent protein kinase with antisense oligodeoxynucleotides: consequences for the rejoining of radiation-induced DNA double-strand breaks and radiosensitivity of human cancer cell lines. Cancer Res. 2002;62:6621–6624
  118. Kim CH, Park SJ, Lee SH. A targeted inhibition of DNA-dependent protein kinase sensitizes breast cancer cells following ionizing radiation. J Pharmacol Exp Ther. 2002;303:753–759
  119. Hickson I, Zhao Y, Cockcroft X, Curtin NJ, Green SJ, Hummersone M, et al. Identification and in vitro characterisation of a novel and specific inhibitor of the ataxia-telangiectasia mutated kinase ATM. American Association for Cancer Research (Abstract No. 5360); 2004.
  120. Chow TY, Alaoui-Jamali MA, Yeh C, Yuen L, Griller D. The DNA double-stranded break repair protein endo-exonuclease as a therapeutic target for cancer. Mol Cancer Ther. 2004;3:911–919
  121. Siddik ZH. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene. 2003;22:7265–7279
  122. Selvakumaran M, Pisarcik DA, Bao R, Yeung AT, Hamilton TC. Enhanced cisplatin cytotoxicity by disturbing the nucleotide excision repair pathway in ovarian cancer cell lines. Cancer Res. 2003;63:1311–1316
  123. Ferrer M, de Winter JP, Mastenbroek DC, Curiel DT, Gerritsen WR, Giaccone G, et al. Chemosensitizing tumor cells by targeting the Fanconi anemia pathway with an adenovirus overexpressing dominant-negative FANCA. Cancer Gene Ther. 2004;11:539–546
  124. Moufarij MA, Phillips DR, Cullinane C. Gemcitabine potentiates cisplatin cytotoxicity and inhibits repair of cisplatin-DNA damage in ovarian cancer cell lines. Mol Pharmacol. 2003;63:862–869
  125. Crul M, van Waardenburg RC, Bocxe S, van Eijndhoven MA, Pluim D, Beijnen JH, et al. DNA repair mechanisms involved in gemcitabine cytotoxicity and in the interaction between gemcitabine and cisplatin. Biochem Pharmacol. 2003;65:275–282
  126. Jiang H, Yang LY. Cell cycle checkpoint abrogator UCN-01 inhibits DNA repair: association with attenuation of the interaction of XPA and ERCC1 nucleotide excision repair proteins. Cancer Res. 1999;59:4529–4534
  127. Andrews BJ, Turchi JJ. Development of a high-throughput screen for inhibitors of replication protein A and its role in nucleotide excision repair. Mol Cancer Ther. 2004;3:385–391
  128. Zhong X, Li QQ, Reed E. SU5416 sensitizes ovarian cancer cells to cisplatin through inhibition of nucleotide excision repair. Cell Mol Life Sci. 2003;60:794–802
  129. Friedmann B, Caplin M, Hartley JA, Hochhauser D. Modulation of DNA repair in vitro after treatment with chemotherapeutic agents by the epidermal growth factor receptor inhibitor gefitinib (ZD1839). Clin Cancer Res. 2004;10:6476–6486
  130. Plumb JA, Strathdee G, Sludden J, Kaye SB, Brown R. Reversal of drug resistance in human tumor xenografts by 2′-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter. Cancer Res. 2000;60:6039–6044
  131. Plumb JA, Steele N, Finn PW, Brown R. Epigenetic approaches to cancer therapy. Biochem Soc Trans. 2004;32:1095–1097
  132. Matheson SL, McNamee J, Jean-Claude BJ. Design of a chimeric 3-methyl-1,2,3-triazene with mixed receptor tyrosine kinase and DNA damaging properties: a novel tumor targeting strategy. J Pharmacol Exp Ther. 2001;296:832–840
  133. Matheson SL, McNamee JP, Jean-Claude BJ. Differential responses of EGFR-/AGT-expressing cells to the “combi-triazene” SMA41. Cancer Chemother Pharmacol. 2003;51:11–20
  134. Brahimi F, Matheson SL, Dudouit F, McNamee JP, Tari AM, Jean-Claude BJ. Inhibition of epidermal growth factor receptor-mediated signaling by “Combi-triazene” BJ2000, a new probe for Combi-Targeting postulates. J Pharmacol Exp Ther. 2002;303:238–246

PII: S0305-7372(05)00174-X

doi: 10.1016/j.ctrv.2005.09.006

Cancer Treatment Reviews
Volume 31, Issue 8 , Pages 603-617 , December 2005

Article Tools

* Image Usage & Resolution